We analysed this further and separately assessed cancer incidence in participants with known type 2 diabetes (already using glucose-lowering medication and/or insulin) and those with screen-detected diabetes, e.g. those with elevated fasting blood glucose or HbA1c at baseline Lifelines screening. This evidence concerns the gene INS and type 2 diabetes mellitus.